{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:38:52Z","timestamp":1792219132784,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272757"],"award-info":[{"award-number":["82272757"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69695-4","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:45:34Z","timestamp":1771919134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-6646","authenticated-orcid":false,"given":"Xin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7174-5366","authenticated-orcid":false,"given":"Somaira","family":"Nowsheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4393-7296","authenticated-orcid":false,"given":"Fan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1938-3091","authenticated-orcid":false,"given":"Zhenkun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-9775","authenticated-orcid":false,"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"69695_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein, A. P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat. Rev. Gastroenterol. Hepatol. 18, 493\u2013502 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"69695_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel, E. M., Brand, R. E. & Goggins, M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 164, 752\u2013765 (2023).","journal-title":"Gastroenterology"},{"key":"69695_CR3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet 395, 2008\u20132020 (2020).","journal-title":"Lancet"},{"key":"69695_CR4","first-page":"375","volume":"70","author":"AJ Grossberg","year":"2020","unstructured":"Grossberg, A. J. et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J. Clin. 70, 375\u2013403 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"69695_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"69695_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41586-023-06954-0","volume":"626","author":"C Weng","year":"2024","unstructured":"Weng, C., Faure, A. J., Escobedo, A. & Lehner, B. The energetic and allosteric landscape for KRAS inhibition. Nature 626, 643\u2013652 (2024).","journal-title":"Nature"},{"key":"69695_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17\u201333 (2017).","journal-title":"Cell"},{"key":"69695_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig, M. N., Ashwood, L. M., Kondrashova, O. & Sutherland, K. D. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer 9, 955\u2013967 (2023).","journal-title":"Trends Cancer"},{"key":"69695_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie, H., Gagnon, J. & Therrien, M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat. Rev. Mol. Cell Biol. 21, 607\u2013632 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"69695_CR10","doi-asserted-by":"publisher","unstructured":"Dilly, J. et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0177 (2024).","DOI":"10.1158\/2159-8290.CD-24-0177"},{"key":"69695_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1053\/j.gastro.2013.01.071","volume":"144","author":"MP di Magliano","year":"2013","unstructured":"di Magliano, M. P. & Logsdon, C. D. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 144, 1220\u20131229 (2013).","journal-title":"Gastroenterology"},{"key":"69695_CR12","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.21.02752","volume":"40","author":"SI Ou","year":"2022","unstructured":"Ou, S. I. et al. First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1). J. Clin. Oncol. 40, 2530\u20132538 (2022).","journal-title":"J. Clin. Oncol."},{"key":"69695_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33\u201343 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69695_CR14","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457\u20132467 (2012).","journal-title":"Cancer Res."},{"key":"69695_CR15","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","volume":"42","author":"HF Hu","year":"2021","unstructured":"Hu, H. F. et al. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol. Sin. 42, 1725\u20131741 (2021).","journal-title":"Acta Pharmacol. Sin."},{"key":"69695_CR16","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3390\/cells11193175","volume":"11","author":"H Shen","year":"2022","unstructured":"Shen, H. et al. KRAS G12D mutation subtype in pancreatic ductal adenocarcinoma: does it influence prognosis or stage of disease at presentation? Cells 11, 3175 (2022).","journal-title":"Cells"},{"key":"69695_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49915-5","volume":"15","author":"JE Till","year":"2024","unstructured":"Till, J. E. et al. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 15, 5763 (2024).","journal-title":"Nat. Commun."},{"key":"69695_CR18","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J. Med. Chem. 65, 3123\u20133133 (2022).","journal-title":"J. Med. Chem."},{"key":"69695_CR19","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat. Med. 28, 2171\u20132182 (2022).","journal-title":"Nat. Med."},{"key":"69695_CR20","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","volume":"83","author":"KCM Gulay","year":"2023","unstructured":"Gulay, K. C. M. et al. Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 83, 3001\u20133012 (2023).","journal-title":"Cancer Res."},{"key":"69695_CR21","doi-asserted-by":"publisher","unstructured":"Becker, J. H. et al. Targeting BCL2 with venetoclax enhances the efficacy of the KRASG12D inhibitor MRTX1133 in pancreatic cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3574 (2024).","DOI":"10.1158\/0008-5472.CAN-23-3574"},{"key":"69695_CR22","doi-asserted-by":"publisher","first-page":"B077","DOI":"10.1158\/1538-7445.PANCA2023-B077","volume":"84","author":"HY Khan","year":"2024","unstructured":"Khan, H. Y. et al. Abstract B077: KRASG12D inhibitor MRTX1133 synergizes with the next generation nuclear transport protein inhibitor eltanexor resulting in enhanced antitumor activity against pancreatic ductal adenocarcinoma. Cancer Res. 84, B077 (2024).","journal-title":"Cancer Res."},{"key":"69695_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e16301","volume":"41","author":"V Tajiknia","year":"2023","unstructured":"Tajiknia, V. et al. Combination of 5-FU plus KRAS G12D inhibitor MRTX1133 against human colorectal and pancreatic cancer cells and the affects on inhibition of pERK and immune-stimulatory cytokine patterns in in KRAS G12D and KRAS G12V tumor cells. J. Clin. Oncol. 41, e16301 (2023).","journal-title":"J. Clin. Oncol."},{"key":"69695_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160\u2013166 (2023).","journal-title":"Nature"},{"key":"69695_CR25","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/nar\/gkl010","volume":"34","author":"CX Deng","year":"2006","unstructured":"Deng, C. X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34, 1416\u20131426 (2006).","journal-title":"Nucleic Acids Res."},{"key":"69695_CR26","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1016\/j.molcel.2022.07.010","volume":"82","author":"R Bhowmick","year":"2022","unstructured":"Bhowmick, R. et al. RAD51 protects human cells from transcription-replication conflicts. Mol. Cell 82, 3366\u20133381 (2022).","journal-title":"Mol. Cell"},{"key":"69695_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17324-z","volume":"11","author":"M Berti","year":"2020","unstructured":"Berti, M. et al. Sequential role of RAD51 paralog complexes in replication fork remodeling and restart. Nat. Commun. 11, 3531 (2020).","journal-title":"Nat. Commun."},{"key":"69695_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-genet-021920-092410","volume":"54","author":"B Bonilla","year":"2020","unstructured":"Bonilla, B., Hengel, S. R., Grundy, M. K. & Bernstein, K. A. RAD51 gene family structure and function. Annu. Rev. Genet. 54, 25\u201346 (2020).","journal-title":"Annu. Rev. Genet."},{"key":"69695_CR29","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","volume":"50","author":"JR Infante","year":"2014","unstructured":"Infante, J. R. et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur. J. Cancer 50, 2072\u20132081 (2014).","journal-title":"Eur. J. Cancer"},{"key":"69695_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.coc.0000251235.46149.43","volume":"30","author":"RDW Marsh","year":"2007","unstructured":"Marsh, R. D. W. et al. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol. 30, 26\u201331 (2007).","journal-title":"Am. J. Clin. Oncol."},{"key":"69695_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"69695_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp, S. B. et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 13, 298\u2013311 (2023).","journal-title":"Cancer Discov."},{"key":"69695_CR33","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell 41, 1606\u20131620 (2023).","journal-title":"Cancer Cell"},{"key":"69695_CR34","unstructured":"A phase 1\/2 multiple expansion cohort trial of MRTX1133 in patients with advanced solid tumors harboring a KRAS G12D mutation. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05737706 (2023)."},{"key":"69695_CR35","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou, C. et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell 42, 1286\u20131300 (2024).","journal-title":"Cancer Cell"},{"key":"69695_CR36","doi-asserted-by":"publisher","first-page":"TPS3172","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3172","volume":"42","author":"A Patnaik","year":"2024","unstructured":"Patnaik, A. et al. A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. J. Clin. Oncol. 42, TPS3172 (2024).","journal-title":"J. Clin. Oncol."},{"key":"69695_CR37","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim, Y. H. et al. PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2, 1036\u20131047 (2012).","journal-title":"Cancer Discov."},{"key":"69695_CR38","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-15-1772","volume":"22","author":"W Mo","year":"2016","unstructured":"Mo, W. et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin. Cancer Res. 22, 1699\u20131712 (2016).","journal-title":"Clin. Cancer Res."},{"key":"69695_CR39","doi-asserted-by":"publisher","first-page":"11592","DOI":"10.18632\/oncotarget.24294","volume":"9","author":"F Vena","year":"2018","unstructured":"Vena, F. et al. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget 9, 11592\u201311603 (2018).","journal-title":"Oncotarget"},{"key":"69695_CR40","doi-asserted-by":"publisher","first-page":"101335","DOI":"10.1016\/j.jbc.2021.101335","volume":"297","author":"JN Diehl","year":"2021","unstructured":"Diehl, J. N. et al. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. J. Biol. Chem. 297, 101335 (2021).","journal-title":"J. Biol. Chem."},{"key":"69695_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal5148","volume":"9","author":"C Sun","year":"2017","unstructured":"Sun, C. et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci. Transl. Med. 9, eaal5148 (2017).","journal-title":"Sci. Transl. Med."},{"key":"69695_CR42","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. 23, 3711\u20133720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"69695_CR43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","volume":"2","author":"AK Mehta","year":"2021","unstructured":"Mehta, A. K. et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat. Cancer 2, 66\u201382 (2021).","journal-title":"Nat. Cancer"},{"key":"69695_CR44","unstructured":"Phase 1\/1b, multicenter, open-label, study of RMC 9805 in participants with advanced KRASG 12D-mutant solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05917262 (2023)."},{"key":"69695_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads0239","volume":"389","author":"C Weller","year":"2025","unstructured":"Weller, C. et al. A neomorphic protein interface catalyzes covalent inhibition of RAS(G12D) aspartic acid in tumors. Science 389, eads0239 (2025).","journal-title":"Science"},{"key":"69695_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb2630","volume":"6","author":"M Deng","year":"2020","unstructured":"Deng, M. et al. Extracellular matrix stiffness determines DNA repair efficiency and cellular sensitivity to genotoxic agents. Sci. Adv. 6, eabb2630 (2020).","journal-title":"Sci. Adv."},{"key":"69695_CR47","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"69695_CR48","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res. 52, D672\u2013D678 (2024).","journal-title":"Nucleic Acids Res"},{"key":"69695_CR49","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203 (2017)."},{"key":"69695_CR50","unstructured":"CNCB-NGDC Members and Partners. Database resources of the National Genomics Data Center, China National Center for Bioinformation in 2025. Nucleic Acids Res. 53, D30\u2013D44 (2025)."}],"updated-by":[{"DOI":"10.1038\/s41467-026-72371-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69695-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69695-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69695-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:03:32Z","timestamp":1776927812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69695-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69695"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69695-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-026-72371-2","URL":"https:\/\/doi.org\/10.1038\/s41467-026-72371-2","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3118"}}